Tomasz Sablinski, MD, PhD — Chief Executive Officer
Tomasz Sablinski has 35 years of experience in healthcare. This includes 20 years of pharmaceutical development at Novartis, overseeing clinical development projects at Parexel, consulting for biotechnology companies and managing a development portfolio at Auven Therapeutics. In the 1990s Dr. Sablinski was a member of teams at Harvard Medical School (Brigham and Women’s and Massachusetts General Hospitals) conducting pioneering work in developing biologic immunosuppressive regimens, induction of transplantation tolerance and xenotransplantation. He also practiced as a surgeon specializing in renal transplantation and general surgery in his native Poland and in Boston. Dr. Sablinski received his MD and PhD degrees from the Medical University of Warsaw in Poland. In parallel to his role at TLS, he currently serves as head of development and a managing director of Auven Therapeutics.
Marc Foster, MBA — Chief Operating Officer
Marc Foster brings 15 years of biotech and 15 years of high-tech experience to TLS. Most recently, he served as a senior business development and technology advisor to FoldRx Pharmaceuticals, where he helped craft and implement the business development strategy of the company’s protein misfolding pipeline and discovery platform, leading to an acquisition by Pfizer in 2010. Mr. Foster began his biotech career working on behalf of Schrodinger in product development. Subsequently he co-founded and built Reify Corporation, developer of high-content assay systems for pre-clinical discovery and toxicology. During his high-tech career Mr. Foster held operating, co-founding, and advisory roles with numerous firms that created substantial shareholder value through acquisition or public offering, including NETBot, Apropos, and InTouch Systems. Mr. Foster holds a BS in Electrical Engineering and a BA in English from Brown University, and an MBA in Finance from The University of Chicago Booth School of Business. He served as a Research Fellow at BIDMC/Harvard Medical School in Endocrinology.
Susan Wong, PA — Senior Director, Clinical Operations
Susan Wong brings over 20 years of industry experience to TLS. She has served in leadership roles in Clinical Operations, Development, Project Management and Compliance. For the past four years, Susan has been developing the strategic and operational aspects of executing decentralized, virtual clinical trials. She has worked in large and small companies, including sites, sponsors and CROs, and therapeutic areas ranging from cardiovascular, neurology, endocrine, and oncology. Throughout her career, Susan has participated in medical mission excursions to remote and underserved areas globally. Susan received her Bachelor of Science degree from UCLA and obtained a Physician Assistant (PA) certification from USC, specializing in emergency medicine.
Donna Thornton, MBA — Vice President, Business Development
Donna brings over 20 years of experience in the health sciences industry. Previously, she led business development efforts for nine years at Oracle concentrating on a platform of SaaS clinical trial applications. In addition to technology expertise, Donna has a deep understanding of clinical trial execution from leading business development efforts at Covance for greater than 6 years. Her combination of technology and CRO service knowledge fosters unique insight into the adoption of all-digital innovation. Donna serves as an executive on the Board of Women Visitors for the University of Pennsylvania Health System and as Committee Representative for the Abramson Cancer Care Center. Donna earned her Bachelor’s degree from Temple University and her MBA degree from Philadelphia University.
Stuart Barlow, MBA, CPA, CGMA — Chief Financial Officer
Stuart Barlow brings 10 years of senior financial management in drug development to TLS, following his role as Chief Accounting Officer for Auven Therapeutics Holdings LP, an international private equity fund engaged in cancer, ophthalmic, and orphan drug development. Prior to Auven, Mr. Barlow had public and private company controllership responsibilities in the health insurance, consumer packaged goods, and consumer electronics industries. Mr. Barlow holds a BA in political science from Boston University and an MBA in Finance and Accounting from the Columbia University School of Business Administration. He is a CPA licensed in New York State, a Chartered Global Management Accountant, and a member of Financial Executives International.
Lawrence Steinman, MD — Chairman, Scientific Advisory Board
Lawrence Steinman is a professor of neurology and neurological sciences, pediatrics, and genetics at Stanford School of Medicine. He is also the chair of the Stanford University Program in Immunology. Dr. Steinman’s research focuses on what provokes relapses and remissions in multiple sclerosis (MS), the nature of the genes that serve as a brake on brain inflammation, and the quest for a vaccine against MS. He has developed two antigen specific therapies, using DNA vaccines, for MS and type 1 diabetes. He was senior author on the seminal 1992 Nature article that reported the key role of a particular integrin in brain inflammation. This research led to the development of the drug Tysabri, which is used to treat patients with MS and Crohn’s disease. Dr. Steinman holds a number of patents in the areas of immunology, and for therapies of Huntington disease and MS. He cofounded Tolerion, Neurocrine Biosciences, Bayhill Therapeutics, and Nuon Therapeutics. Dr. Steinman received his BA from Dartmouth College and his MD from Harvard University.
Richard Warburg, PhD — Partner, New Ventures III
Richard Warburg has served as a Partner at Auven Therapeutics, and Head of Intellectual Property at ADC Therapeutics. He serves as an Advisor of Gensys Software, Inc. Previously, Dr. Warburg was a Partner at the law firms of Foley & Lardner LLP and Lyon & Lyon. He attended Suffolk University Law School, and is a graduate of Birmingham University, England, where he completed his Ph.D. in Molecular Biology.
Harry Glorikian — Partner, New Ventures III
Harry has been the Managing Director of Strategy and Personalized Medicine at Precision for Medicine, Inc. since joining in December 2012. Mr. Glorikian has more than 20 years of experience in the health care and life science industries. He holds a BSBA and MBA from Boston University and a BA in General Biology from San Francisco State University.
John Watson — Corporate Senior Vice President, Chief Commercial Officer and President – Strategic Partnering, Covance (Retired)
John Watson has over 33 years of commercial and executive leadership experience in the healthcare services industry working with biopharmaceutical companies, clinics, and hospital-based providers. He retired from the Covance Drug Development division of LabCorp in September 2015 after 16 years as a Senior Corporate Vice President, Chief Commercial Officer and President of Strategic Partnering. His responsibilities spanned the company’s commercial activities, including sales, client services, marketing, alliance management and strategic partnering covering the portfolio of Covance Drug Development’s services. Mr. Watson was the executive sponsor and lead negotiator for the two largest R&D outsourcing partnerships in the CRO industry with the 10-year Lilly agreement in 2008 for $1.6B and the ten year Sanofi agreement in 2010 for $2.2B. Mr. Watson has an in-depth knowledge of the CRO and biopharmaceutical industries and has leveraged that knowledge to drive significant growth at Covance Inc., which resulted in the sale to LabCorp in February 2015. Prior to joining Covance Inc., Mr. Watson spent 12 years with E.R. Squibb & Sons, BMS and Bracco Diagnostics. Mr. Watson attended Louisiana State University earning a B.S. in Marketing and currently serves on the Dean’s Advisory Board for the E. J. Ourso College of Business.
Tomasz Sablinski, MD, PhD
Chris Adams — Co-founder, Cydan Development
Chris Adams is a co-founder and chief business officer of Cydan Development Inc. Prior to joining Cydan, Dr. Adams was president of CMA Biotech Consulting where he worked in advisory roles for a number of development stage orphan drug companies. Previously, Dr. Adams was chief business officer of FoldRx Pharmaceuticals Inc., where he was responsible for business strategy, licensing and business development, as well as pre-commercial activities for VYNDAQEL® (tafamidis), a treatment for Transthyretin Amyloidosis. He led the M&A process, which resulted in the acquisition of the company by Pfizer for October of 2010. Dr. Adams has a diploma in organic chemistry and biochemistry and a PhD in organic chemistry from the University of Zurich. Dr. Adams also holds an MBA from INSEAD of Fontainebleau, France.
Scott Becker — Co-Founder, Chief Business Officer at Delve Therapeutics
Scott is an entrepreneur and angel investor. He is co-founder and CBO at Delve Therapeutics, a discovery stage company working with oncolytic viruses. Prior to Delve, Scott was the VP of Enterprise Products at Schrodinger, the leading computational chemistry company – which has been involved in the discovering of multiple first-in-class clinical stage assets. He was also Co-Founder and CTO of Invite Media, a venture backed computational advertising startup that was acquired by Google.
Paul has over 40 years of experience in fund management, focussing on equity markets and global policy. He was appointed an Investment Manager at Confederation Life, a Canadian mutual assurance company, where he led a team that established Confederation as a leading office in the UK pensions market. Mr. Gaunt joined the Equitable Life as the Senior Investment Manager and Assistant General Manager with responsibility for global equity policy. Paul also established an Alternative Assets portfolio with a particular emphasis on biotechnology and healthcare markets. In 1997 he resigned in order to pursue private interests. Paul has held a number of non-executive positions in recent years, including terms at Numis Corporation, Oasis Healthcare, JO Hambro Capital Management, The Worldwide Healthcare Trust, Merlin LLP, and BRIT Plc. Paul is currently a non-executive director of the Biotech Growth Trust Plc and the Allianz technology Trust Plc.
Karim Lakhani, PhD — Harvard Business School
Karim R. Lakhani is the Lumry family associate professor of Business Administration at the Harvard Business School and the principal investigator of the Harvard-NASA Tournament Lab at the Institute for Quantitative Social Science. He has extensively studied the emergence of open source software communities and their unique innovation and product development strategies. He has also investigated how critical knowledge from outside of the organization can be accessed through innovation contests. He specializes in the management of technological innovation in firms and communities. Professor Lakhani was awarded his Ph.D. in management from the Massachusetts Institute of Technology. He also holds an MS degree in Technology and Policy from MIT, and a Bachelor’s degree in Electrical Engineering and Management from McMaster University in Canada.
Barbara Lindheim — BLL Partners
Barbara Lindheim is a founder and managing partner at BLL Partners LLC, a consultancy providing strategic communications services to the biotechnology and life sciences industries. Barbara brings her clients more than two decades of industry experience in strategic positioning, corporate and product communications, investor relations and marketing. Her prior experience includes senior strategy and communications roles at BioCom Partners, Orchid BioSciences, Edelman Worldwide, Noonan/Russo Communications, Glaxo SmithKline, Sanofi predecessor company Sterling Winthrop and Pfizer. A graduate of Cornell University, Barbara earned an MBA with distinction from Harvard Business School and a masters in public policy from Princeton University.
Always stay in the loop.
Sign up for our latest updates.